About eMBR Genomics

eMBR Genomics is developing a non-invasive liquid biopsy technology for multi-cancer early detection by analyzing specific cellular structures. This approach aims to improve diagnostic accuracy and enable timely therapeutic interventions for various cancers.

```xml <problem> Current methods for multi-cancer early detection often rely on circulating tumor DNA (ctDNA), which is released by dying cells and can be present in low concentrations, limiting sensitivity. Traditional liquid biopsies may also lack the ability to pinpoint the specific type of cancer present at early stages. </problem> <solution> eMBR Genomics is developing a non-invasive liquid biopsy technology that analyzes midbody remnants (MBRs), RNA-packed extracellular vesicles released during cell division, for multi-cancer early detection. MBRs offer advantages over ctDNA due to their larger size, tissue-specific biological cargo, and production by actively dividing cells. The company's approach involves using proprietary antibodies to detect and isolate MBRs, extracting critical mRNA information to identify the presence of cancer and potentially pinpoint its type. This technology aims to improve diagnostic accuracy and enable timely therapeutic interventions. </solution> <features> - Proprietary antibodies for MBR detection and isolation - Analysis of mRNA cargo within MBRs to identify cancer signals - Technology designed to detect cancers at early stages through liquid biopsy - MBRs are 1000-4000X larger than exosomes by volume - MBRs are produced by actively dividing cells </features> <target_audience> The primary target audience includes researchers, laboratories, and industry leaders in rare diseases and cancer diagnostics seeking to improve early cancer detection through liquid biopsy. </target_audience> ```

What does eMBR Genomics do?

Where is eMBR Genomics located?

eMBR Genomics is based in Madison, United States.

When was eMBR Genomics founded?

eMBR Genomics was founded in 2024.

Who founded eMBR Genomics?

eMBR Genomics was founded by Roman Gelman.

Roman Gelman - CEO

Location

Madison, United States

Founded

2024

Employees

3 employees

Looking for specific startups?

Try our free semantic startup search

eMBR Genomics

Score: 52/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

embrgenomics.com 100+

Founded 2024 – Madison, United States

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (<5)

Roman Gelman

CEO

Company Description

Problem

Current methods for multi-cancer early detection often rely on circulating tumor DNA (ctDNA), which is released by dying cells and can be present in low concentrations, limiting sensitivity. Traditional liquid biopsies may also lack the ability to pinpoint the specific type of cancer present at early stages.

Solution

eMBR Genomics is developing a non-invasive liquid biopsy technology that analyzes midbody remnants (MBRs), RNA-packed extracellular vesicles released during cell division, for multi-cancer early detection. MBRs offer advantages over ctDNA due to their larger size, tissue-specific biological cargo, and production by actively dividing cells. The company's approach involves using proprietary antibodies to detect and isolate MBRs, extracting critical mRNA information to identify the presence of cancer and potentially pinpoint its type. This technology aims to improve diagnostic accuracy and enable timely therapeutic interventions.

Features

Proprietary antibodies for MBR detection and isolation

Analysis of mRNA cargo within MBRs to identify cancer signals

Technology designed to detect cancers at early stages through liquid biopsy

MBRs are 1000-4000X larger than exosomes by volume

MBRs are produced by actively dividing cells

Target Audience

The primary target audience includes researchers, laboratories, and industry leaders in rare diseases and cancer diagnostics seeking to improve early cancer detection through liquid biopsy.